tetano
Editor, Senior Moderator
Pharmaceuticals (Basel)
. 2021 Dec 6;14(12):1272.
doi: 10.3390/ph14121272.
Monoclonal Antibodies against SARS-CoV-2: Current Scenario and Future Perspectives
Eugenia Quiros-Roldan[SUP] 1 [/SUP], Silvia Amadasi[SUP] 1 [/SUP], Isabella Zanella[SUP] 2 [/SUP], Melania Degli Antoni[SUP] 1 [/SUP], Samuele Storti[SUP] 1 [/SUP], Giorgio Tiecco[SUP] 1 [/SUP], Francesco Castelli[SUP] 1 [/SUP]
Affiliations
Abstract
Monoclonal antibodies (mAbs) have been known since the 1970s. However, their therapeutic potential in the medical field has recently emerged, with the advancement of manufacturing techniques. Initially exploited mainly in the oncology field, mAbs have become increasingly relevant in Infectious Diseases. Numerous mAbs have been developed against SARS-CoV 2 and have proven their effectiveness, especially in the management of the mild-to-moderate disease. In this review, we describe the monoclonal antibodies currently authorized for the treatment of the coronavirus disease 19 (COVID-19) and offer an insight into the clinical trials that led to their approval. We discuss the mechanisms of action and methods of administration as well as the prophylactic and therapeutic labelled indications (both in outpatient and hospital settings). Furthermore, we address the critical issues regarding mAbs, focusing on their effectiveness against the variants of concern (VoC) and their role now that a large part of the population has been vaccinated. The purpose is to offer the clinician an up-to-date overview of a therapeutic tool that could prove decisive in treating patients at high risk of progression to severe disease.
Keywords: SARS-CoV-2; monoclonal antibodies; prophylaxis; therapy; variants.
. 2021 Dec 6;14(12):1272.
doi: 10.3390/ph14121272.
Monoclonal Antibodies against SARS-CoV-2: Current Scenario and Future Perspectives
Eugenia Quiros-Roldan[SUP] 1 [/SUP], Silvia Amadasi[SUP] 1 [/SUP], Isabella Zanella[SUP] 2 [/SUP], Melania Degli Antoni[SUP] 1 [/SUP], Samuele Storti[SUP] 1 [/SUP], Giorgio Tiecco[SUP] 1 [/SUP], Francesco Castelli[SUP] 1 [/SUP]
Affiliations
- PMID: 34959672
- DOI: 10.3390/ph14121272
Abstract
Monoclonal antibodies (mAbs) have been known since the 1970s. However, their therapeutic potential in the medical field has recently emerged, with the advancement of manufacturing techniques. Initially exploited mainly in the oncology field, mAbs have become increasingly relevant in Infectious Diseases. Numerous mAbs have been developed against SARS-CoV 2 and have proven their effectiveness, especially in the management of the mild-to-moderate disease. In this review, we describe the monoclonal antibodies currently authorized for the treatment of the coronavirus disease 19 (COVID-19) and offer an insight into the clinical trials that led to their approval. We discuss the mechanisms of action and methods of administration as well as the prophylactic and therapeutic labelled indications (both in outpatient and hospital settings). Furthermore, we address the critical issues regarding mAbs, focusing on their effectiveness against the variants of concern (VoC) and their role now that a large part of the population has been vaccinated. The purpose is to offer the clinician an up-to-date overview of a therapeutic tool that could prove decisive in treating patients at high risk of progression to severe disease.
Keywords: SARS-CoV-2; monoclonal antibodies; prophylaxis; therapy; variants.